Kyvor Genomics Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.11 M
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth 15.83%
- Profit Growth 30.31%
- Ebitda 431.96%
- Net Worth -30.62%
- Total Assets -18.93%
About Kyvor Genomics
Kyvor Genomics Private Limited (KGPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 August 2013 and has a history of 11 years and six months. Its registered office is in Madurai, Tamil Nadu, India.
The Corporate was formerly known as Lab P53 Cancer Research Private Limited. The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.11 M, as per Ministry of Corporate Affairs (MCA) records.
Abilesh Malli, Jayanthi Malli, and Dimple Jain serve as directors at the Company.
Company Details
- Location
Madurai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74900TN2013PTC092565
- Company No.
092565
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 2013
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Kyvor Genomics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayanthi Malli  | Director | 16-Aug-2013 | Current |
| Abilesh Malli | Director | 16-Aug-2013 | Current |
| Dimple Jain | Additional Director | 22-Oct-2018 | Current |
Financial Performance of Kyvor Genomics.
Kyvor Genomics Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 15.83% increase. The company also saw a substantial improvement in profitability, with a 30.31% increase in profit. The company's net worth observed a substantial decline by a decrease of 30.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kyvor Genomics?
In 2021, Kyvor Genomics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Snd Ventures LlpDimple Jain is a mutual person
- Stpl Solutions Llp
Dimple Jain is a mutual person
- Stpl Power Services Llp
Dimple Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kyvor Genomics?
Unlock and access historical data on people associated with Kyvor Genomics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kyvor Genomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kyvor Genomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
